Only ViaCyte and Bluebird deemed worthy first recipients of CIRM stem cell grants
This article was originally published in Scrip
Executive Summary
The California Institute of Regenerative Medicine (CIRM) initiated the Strategic Partnership Awards in April to give as many as three companies up to $10 million each to move stem cell therapies out of research labs and into the clinic, but the governing board determined on 25 October that only two companies were worthy strategic partners for the state agency.